Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC…


BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

See the rest here:
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC...

Related Posts